ASCO 2024: aanbevolen abstracten gerelateerd aan borstkanker door vooraanstaande oncologen wereldwijd

Aankomende week is er weer ASCO van 31 mei - 4 Juni 2024. Vooraanstaande oncologen wereldwijd bevelen specifieke abstracten aan gerelateerd aan borstkanker.

Voor loco-regionale vormen van borstkanker klik op deze PDF met 132 abstracten. Voor uitgezaaide borstkanker zijn er 141 abstracten, klik daarvoor op deze PDF. Er wordt geen onderscheid gemaakt in wel of niet hormoongevoelige borstkanker.

Hier plaats ik de aanbevolen abstracten door oncologen wereldwijd. Klik op de nummers van het abstract voor het abstract in te zien.

Als eerste de aanbevolen abstracten van Dr. Reshma Mahtani, Chief of Breast Medical Oncology aan het Miami Cancer Institute en een Associate Editor van het PracticeUpdate Center of Excellence for Metastatic Breast Cancer.

Dr. Reshma Mahtani recommends the following abstracts being presented at this year’s ASCO Annual Meeting, held May 31 through June 4, 2024, in Chicago.

Friday, May 31, 2024; 2:45 PM–4:15 PM CDT
Rapid Oral Abstract Session
Breast Cancer—Local/Regional/Adjuvant

512 Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial. DA Yardley, M Untch, CH Barrios, et al

Patients with high-risk node-negative breast cancer will soon have the opportunity to receive ribociclib in combination with endocrine therapy as adjuvant therapy. A better understanding of the baseline characteristics of patients included in the trial and efficacy and safety in this subgroup will be critical to assist patients and physicians in making decisions regarding this important new treatment option.

Saturday, June 1, 2024; 3:00 PM–6:00 PM CDT
Oral Abstract Session
Breast Cancer—Metastatic

LBA1001 Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. K Kalinsky, G Bianchini, EP Hamilton, et al

Due to conflicting results from smaller phase II trials, continuation of a CDK4/6 inhibitor post progression is not considered standard of care and is therefore utilized in select clinical scenarios. This trial will provide important information regarding the effectiveness of this approach in a large randomized phase III trial.

Sunday, June 2, 2024; 7:30 AM–8:00 AM CDT
Oral Abstract Session
Breast Cancer, Special Sessions

LBA1000 Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). G Curigliano, X Hu, R Dent, et al

A recent press release indicated that trastuzumab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH−) metastatic breast cancer following one or more lines of endocrine therapy. This trial is potentially practice-changing, as it may support the use of this highly effective antibody–drug conjugate as first-line therapy for patients with endocrine-refractory disease.

Aanbevolen abstracten gerelateerd aan borstkanker van Dr. Lee Schwartzberg, hoofd medische oncologie en hematologie aan het Renown Institute for Cancer en hoogleraar klinische geneeskunde aan de Universiteit van Nevada, Reno.

Dr. Lee Schwartzberg recommends the following abstracts being presented at this year’s ASCO Annual Meeting

Saturday, June 1, 2024; 3:00 PM–6:00 PM CDT
Oral Abstract Session
Breast Cancer—Metastatic

It has been unclear if a second CDK 4/6 inhibitor adds meaningfully in the second-line setting after a CDK 4/6 inhibitor and endocrine therapy. This study should definitively answer the question, and it may demonstrate subgroups who might derive greater or lesser benefit to guide treatment choice.

Sunday, June 2, 2024; 7:30 AM–8:00 AM CDT
Oral Abstract Session
Breast Cancer, Special Sessions

This may establish T-Dxd as a first-line chemotherapy choice (it is currently recommended in the second line) in this large group of patients with metastatic breast cancer. It may also further extend the group of patients eligible for T-Dxd if patients with ultralow HER2 expression also benefit from the drug over treatment of physician’s choice.

Monday, June 3, 2024; 3:00 PM–6:00 PM CDT
Oral Abstract Session
Breast Cancer—Local/Regional/Adjuvant

LBA500 A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy. PF Conte, MV Dieci, G Bisagni, et al

The benefit of immunotherapy given in the adjuvant setting after neoadjuvant chemotherapy without immunotherapy is unclear. Also unclear is whether there is benefit for high-risk patients who go to primary surgery first and then get adjuvant chemotherapy. This trial will provide the first results to answer these questions.

Professor Lillie Shockney, University Distinguished Service Professor of Breast Cancer at Johns Hopkins and Associate Editor of the PracticeUpdate Center of Excellence Metastatic Breast Cancer.

Aanbevolen abstracten gerelateerd aan borstkanker van Professor Lillie Shockney, Associate Editor van het PracticeUpdate Center of Excellence Metastatic Breast Cancer:

Saturday, June 1, 2014; 9:00 AM–12:00 PM CDT
Poster Session
Care Delivery and Quality Care

1590 Use of surgery for de novo metastatic breast cancer (mBC). J Dickerson, H Tang, C Thompson, et al

Saturday, June 1, 2024; 3:00 PM–6:00 PM CDT
Oral Abstract Session
Breast Cancer–Metastatic

1003 First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses. D Juric, K Kalinsky, N Turner, et al

1007 Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD). T Yamashita, S Saji, T Takano, et al

Monday, June 3, 2024; 1:30 PM–4:30 PM CDT
Poster Session
Symptom Science and Palliative Care

12101 Disclosure of metastatic breast cancer information: Patients’ understanding and patients’ and oncologists’ experiences. F Mesa-Chavez, G Carrillo, D Vazquez Juarez, et al

Dr. Ben Anderson, Professor Emeritus of Surgery and Global Health Medicine at the University of Washington in Seattle and member of the Advisory Board for PracticeUpdate Oncology, recommends the following presentations at the upcoming ASCO Annual Meeting

Dr. Ben Anderson noemt 1 abstract gerelateerd aan borstkanker:

Sunday, June 2, 2024; 9:00 AM–12:00 PM CDT
Poster Session
Breast Cancer—Metastatic

1046 Deciphering the global landscape of breast cancer in 38 OECD countries from 1990-2019: A benchmarking global analysis. P Vemparala, SB Sonani, P Bathvar, et al

Applying the Global Burden of Disease framework, Dr. Vemparala and colleagues have provided a comprehensive analysis of the incidence, prevalence, and life-years lost to breast cancer in 38 countries, highlighting the rising impact that breast cancer is having at the global level and providing vital information to policymakers who have the opportunity to favorably impact breast cancer outcomes.

ASCO 2024, aanbevolen abstracten, borstkanker